Cargando…

The Role of Vitamin K in Cholestatic Liver Disease

Vitamin K (VK) is a ligand of the pregnane X receptor (PXR), which plays a critical role in the detoxification of xenobiotics and metabolism of bile acids. VK(1) may reduce the risk of death in patients with chronic liver failure. VK deficiency is associated with intrahepatic cholestasis, and is alr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sultana, Halima, Komai, Michio, Shirakawa, Hitoshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8400302/ https://www.ncbi.nlm.nih.gov/pubmed/34444675 http://dx.doi.org/10.3390/nu13082515

Ejemplares similares

Effects of Vitamin K(2) on the Expression of Genes Involved in Bile Acid Synthesis and Glucose Homeostasis in Mice with Humanized PXR
por: Sultana, Halima, et al.
Publicado: (2018)

Beneficial Effects of Vitamin K Status on Glycemic Regulation and Diabetes Mellitus: A Mini-Review
por: Ho, Hsin-Jung, et al.
Publicado: (2020)

Effect of Vitamin K-Mediated PXR Activation on Drug-Metabolizing Gene Expression in Human Intestinal Carcinoma LS180 Cell Line
por: Sultana, Halima, et al.
Publicado: (2021)

Geranylgeraniol Inhibits Lipopolysaccharide-Induced Inflammation in Mouse-Derived MG6 Microglial Cells via NF-κB Signaling Modulation
por: Saputra, Wahyu Dwi, et al.
Publicado: (2021)

The Role of Inflammation in Cholestatic Liver Injury
por: Chen, Jie, et al.
Publicado: (2023)

S-allyl Cysteine Enhances Testosterone Production in Mice and Mouse Testis-Derived I-10 Cells
por: Rana, Md Masud, et al.
Publicado: (2021)

The Gut-Liver Axis in Cholestatic Liver Diseases
por: Blesl, Andreas, et al.
Publicado: (2021)

Review: Pathogenesis of cholestatic liver diseases
por: Yokoda, Raquel T, et al.
Publicado: (2020)

Liver Transplantation for Patients with Cholestatic Liver Diseases
por: Schöning, Wenzel, et al.
Publicado: (2015)

Update on pharmacotherapies for cholestatic liver disease
por: Ali, Ahmad H., et al.
Publicado: (2016)

Fibrotic Events in the Progression of Cholestatic Liver Disease
por: Wu, Hanghang, et al.
Publicado: (2021)

The Role of Liver Biopsy in Investigation of Cholestatic Liver Disease in Infancy
por: Chaudhry, Zoya, et al.
Publicado: (2019)

Evaluation and Management of Chronic Cholestatic Liver Diseases
por: Rini, Sandra Surya, et al.
Publicado: (2023)

The role of bile acids in cholestatic liver injury
por: Cai, Shi-Ying, et al.
Publicado: (2021)

Current and future therapies for inherited cholestatic liver diseases
por: van der Woerd, Wendy L, et al.
Publicado: (2017)

Cholestatic liver diseases: new targets, new therapies
por: Santiago, Priscila, et al.
Publicado: (2018)

Bile acid-mediated signaling in cholestatic liver diseases
por: Zeng, Jing, et al.
Publicado: (2023)

The Role of Mesothelin in Activation of Portal Fibroblasts in Cholestatic Liver Injury
por: Nishio, Takahiro, et al.
Publicado: (2022)

Recent developments in the management of idiopathic cholestatic liver disease
por: Imam, Mohamad H., et al.
Publicado: (2012)

Fibrosis in Autoimmune and Cholestatic Liver Disease
por: Penz-Österreicher, Melitta, et al.
Publicado: (2011)

Tryptamine, a Microbial Metabolite in Fermented Rice Bran Suppressed Lipopolysaccharide-Induced Inflammation in a Murine Macrophage Model
por: Agista, Afifah Zahra, et al.
Publicado: (2022)

Osteosarcopenia in autoimmune cholestatic liver diseases: Causes, management, and challenges
por: Pugliese, Nicola, et al.
Publicado: (2022)

Regulation of blood pressure and glucose metabolism induced by L-tryptophan in stroke-prone spontaneously hypertensive rats
por: Ardiansyah, et al.
Publicado: (2011)

Menaquinone-4 Suppresses Lipopolysaccharide-Induced Inflammation in MG6 Mouse Microglia-Derived Cells by Inhibiting the NF-κB Signaling Pathway
por: Saputra, Wahyu Dwi, et al.
Publicado: (2019)

Current Therapies for Cholestatic Diseases
por: Méndez-Sánchez, Nahum, et al.
Publicado: (2023)

Impact of Parenteral Lipid Emulsion Components on Cholestatic Liver Disease in Neonates
por: Guthrie, Gregory, et al.
Publicado: (2021)

The Management of Cholestatic Liver Diseases: Current Therapies and Emerging New Possibilities
por: Mazzetti, Marta, et al.
Publicado: (2021)

Risk stratification in autoimmune cholestatic liver diseases: Opportunities for clinicians and trialists
por: Trivedi, Palak J., et al.
Publicado: (2015)

Cholestatic Liver Disease and Pregnancy: A Systematic Review and Meta-Analysis
por: Ferrigno, Bryan, et al.
Publicado: (2022)

Crosstalk between Gut Microbiota and Bile Acids in Cholestatic Liver Disease
por: Shi, Qingmiao, et al.
Publicado: (2023)

Cholestatic liver diseases: An era of emerging therapies
por: Samant, Hrishikesh, et al.
Publicado: (2019)

Guidelines for the Management of Cholestatic Liver Diseases (2021)
por: Lu, Lungen
Publicado: (2022)

Human Hepatocellular response in Cholestatic Liver Diseases
por: Ortiz, Kimberly, et al.
Publicado: (2023)

Cholestatic Liver Disease: Current Treatment Strategies and New Therapeutic Agents
por: Hasegawa, Sho, et al.
Publicado: (2021)

Jaundice revisited: recent advances in the diagnosis and treatment of inherited cholestatic liver diseases
por: Chen, Huey-Ling, et al.
Publicado: (2018)

Nuclear Receptors as Drug Targets in Cholestatic Liver Diseases
por: Halilbasic, Emina, et al.
Publicado: (2013)

Mitochondrial Mutations in Cholestatic Liver Disease with Biliary Atresia
por: Koh, Hong, et al.
Publicado: (2018)

Hypothalamus-Pituitary-Adrenal Dysfunction in Cholestatic Liver Disease
por: Petrescu, Anca D., et al.
Publicado: (2018)

Variation in Bile Microbiome by the Etiology of Cholestatic Liver Disease
por: Tyc, Olaf, et al.
Publicado: (2020)

Novel therapeutic targets for cholestatic and fatty liver disease
por: Trauner, Michael, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_6da5j5krtqk38iuq8crjbjgclf